New drugs are being tested for the treatment of Multiple Myeloma to find the least toxic and most potent one.
Let's talk about how these drugs act.
Mezigdomide, a Cereblon E3 ubiquitin ligase modulator, targets Ikaros and CK1α inhibiting tumor growth.
We need to know more about:
to know about Mezigdomide.
There is a recent study of mezigdomide plus dexamethasone in multiple myeloma patients.primary objectives were to evaluate the safety and efficacy of mezigdomide plus dexamethasone .
results were promising
Regulates signaling pathways related to
cell cycle progression,
differentiation in development,
circadian rhythm(first kinase to have this activity), immune response